PTC Therapeutics Q2 2025: Sephience approved in EU and US; total revenue $179M; net loss narrows

PTC THERAPEUTICS, INC.

2025-Q2 EPS reported $9.29 revenue$1,354,971,000

Sephience (sepiapterin) received EC and FDA approval with broad label for PKU across all ages and subtypes; global launch initiated.
Q2 total revenue $178.9M (vs $186.7M Q2 2024); DMD franchise $96M: Translarna $59.5M, Emflaza $36.4M.
Net loss improved to $64.8M from $99.2M; cash & securities $1.99B (up from $1.14B at Dec 31, 2024).
Entered agreement to buy out Censa sales milestone obligation for $225M upfront plus future milestones.
FY2025 revenue guidance $650-800M; vatiquinone PDUFA date Aug 19, 2025; positive Phase 2 HD results for votoplam.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.